Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
2 Manika Khanna - Chairperson & Managing Director, Rakesh Kumar Sharma - Chief Financial Officer
Analysts
5 Anuj Goyal (Bastion Research), Arman (Bluesky Fintech), Jyotish Nairobi (More Financial Services), Manishkela (Swastik Investments), Priyansh Miri (NGP Family Office), Raman KV (Sequent Investments), Vilay Rai (Kamakya Wealth Management)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹19.4 crores | +9.1% YoY vs ₹17.8 crores in Q1 FY26. Growth driven by higher patient volumes at major hubs, advanced IVF protocols, and international patient contribution. |
| EBITDA | ₹2.4 crores | -52.9% YoY vs ₹5.2 crores in Q1 FY26; margin at 12.5%, contraction of 16.5%. Decline due to front-loaded expansion costs (South Extension, new hubs, clinical talent, AI marketing). Excluding one-offs, EBITDA would have been ~₹5.35 crores with margin ~27.6%. |
| Profit After Tax (PAT) | ₹1.8 crores | -42.3% YoY vs ₹3.1 crores in Q1 FY26. |
| Cash & Bank Balances | ₹8.12 crores | As of 30 June 2026, providing adequate cushion for expansion. |
| Borrowings | ₹6.74 crores | Debt-light structure post IPO. |
| Debt-to-Equity Ratio | ~0.4 times | Comfortable leverage giving flexibility to fund expansion. |
| CAPEX Guidance (FY27) | ~₹25 crores | For 10 new hubs at an average cost of ₹2.5 crores per hub, funded via IPO proceeds and internal accruals. On track. |
| Avg Revenue Per Patient | ₹3.5 - ₹4.0 lakhs | Core IVF revenue per patient; excludes low-value services to reach ~₹4 lakhs. |
| IVF Cycle Cost | ₹2 - ₹20 lakhs | Range of initial package pricing depending on patient medical complexity. |
| New Hub Ramp-up | 30-50 cycles/annum | Expected annual cycles at a mature tier-2 hub (30) and a metro hub (50). |
Geographic & Segment Commentary
- Core IVF Treatment: Anchor of the business. Clinical pregnancy success rate stands at 58%, having grown to 62% in the first attempt. Cumulative pregnancy rates are as high as 85%. Growth is supported by a clinician-led, SOP-driven model refined over 17 years.
- Pharmacy & Hospital Services: Complement the core IVF business. The pharmacy vertical provides fertility medications and consumables; hospital services extend to allied women's health (gynecology, obstetrics, minimally invasive procedures). These segments carry structurally lower margins but deepen patient wallet share and reinforce the comprehensive women's health positioning.
- Expansion Hubs & Spokes: As of date, 8 hubs and 28 spokes operational. The first new hub at South Extension, New Delhi, became operational on July 16, 2026, with the Gurgaon and Nagpur hubs slated to open in ~10 and ~25 days, respectively. Three international spokes (Paris, Nigeria, Sydney) are in progress; international patients currently constitute 25-30% of the patient mix.
Company-Specific & Strategic Commentary
- AI Embryology Integration (Sid & Erica): Formally integrated AI tools, Sid and Erica, into routine clinical practice for the first time in India, in partnership with IVF 2.0. These tools assist in real-time sperm selection and embryo assessment. Early results indicate an ~8% improvement in first-attempt success rates. This is a key differentiator and a first-mover advantage.
- Signature Lab Model: The South Extension center houses the "Gaudium Signature Lab," a proprietary framework integrating AI-embryology with standardized protocols. This model will be replicated at every new center to ensure consistent clinical excellence across tier-1, tier-2, and tier-3 locations.
- Gaudium Women Hospital, Lucknow: The board approved a project cost of up to ₹15 crores for a dedicated women's hospital. The IVF unit will be a core component. Commercialization is expected in FY28-29 and will be funded primarily through internal accruals, not the IPO proceeds earmarked for IVF hubs. Rationale is to extend clinical expertise into the broader women's health segment, addressing a market gap.
- Patient Financing & Awareness: Tie-up with JC Bank to offer patient financing is helping reach patients in tier-2 and tier-3 markets. Strategy includes B2C awareness campaigns to bring first-time patients into the fold, with B2B referrals as an additional growth driver.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (FY27) | ~30% YoY growth | Management is confident of achieving this historical growth rate, despite a slower Q1, due to new hub contributions (South Extension, Gurgaon, Nagpur) ramping up and seasonally stronger Q2 and Q4. This is above the industry CAGR of ~10-12%. |
| EBITDA Margin (FY27) | Sustain FY26 levels | Management expects to return to steady-state EBITDA margins (~27-29%) by the end of the year, as one-off expansion and marketing costs for AI tools normalize and new hubs mature. |
Risks & Constraints
| Risk | Context |
|---|---|
| Execution Risk of Expansion | The ambitious plan to open 10 new hubs in FY27 against a Q1 delivery of just 1 (with 2 more imminent) carries inherent execution risk. Any delay in construction, regulatory approvals, or clinical talent hiring could impact the revenue trajectory and margin recovery. |
| Slower Q1 Growth & Seasonality | Q1 revenue growth was only 9.1% YoY, a significant deceleration from the ~46% growth in FY26. While management attributes this to seasonal weakness (heat) and investment-related distractions, a failure to achieve the typical Q2/Q4 rebound would indicate a structural slowdown rather than seasonality. |
| Regulatory Implementation (ART Act) | The ART (Assisted Reproductive Technology) Act is in various stages of implementation across states. While this is expected to drive consolidation in favor of organized players, the timeline is uncertain. Delays in enforcement could prolong the dominance of the unorganized sector, limiting the expected market share gains. |
| Competitive Pressure | The IVF space is becoming increasingly competitive. The company's strategy relies on clinical outcomes (AI tools) and brand differentiation to stand out. The success of this differentiation strategy in attracting patients away from competitors in new geographies is untested. |
Q&A Highlights
Q1 Growth & FY27 Guidance
- Question: Why was revenue growth only 9% YoY despite a lower base? Do older hubs have peaked? Are you confident of achieving >40% growth for FY27? (Arman, Bluesky Fintech)
- Answer: Q1 growth is impacted by seasonality (heat) and because the company was focused on laying the base for new centers and integrating AI technology. Management reaffirmed guidance of ~30% revenue growth for FY27, citing historical performance and future contributions from new hubs. They expect to sustain EBITDA margins at FY26 levels. (Manika Khanna)
New Hub Breakeven & Lucknow Hospital Rationale
- Question: How long does it take for a new hub to break even, and what was the rationale for entering the hospital business? (Vilay Rai, Kamakya Wealth)
- Answer: New hubs typically break even in 6 months, but historically in 3 months. The Lucknow hospital was chosen because it was already a target for an IVF center, and the company has a long-term vision to extend into dedicated women's health, a segment with few dedicated players. The project is funded via internal accruals and will not disturb the IPO fund allocation for IVF hubs. (Manika Khanna)
Scaling New Centers & Competitive Strategy
- Question: With rising competition, how will you scale new centers? Is marketing the only strategy, or are you also targeting referrals? (Anuj Goyal, Bastion Research)
- Answer: The primary USP is clinical excellence and an SOP-driven model without a "star doctor" approach. AI technology (Sid & Erica) is a key first-mover differentiator. The company also relies on the ART Act consolidation and awareness campaigns to bring new patients into the market. While B2B referrals are being integrated, B2C remains the core strength. (Manika Khanna)
Average Revenue Per Patient
- Question: What is the average revenue per patient if we exclude low-value services? (Manishkela, Swastik Investments)
- Answer: Excluding lower-value services, the average revenue per patient increases to ~₹4 lakhs, assuming fresh cycles only. (Rakesh Kumar Sharma)
Hub Unit Economics & Margin Decline
- Question: What is the capex per hub and expected revenue once ramped up? What caused the margin decline? (Raman KV, Sequent Investments)
- Answer: The average capex per new center is ₹2.5 crores (₹1 crore construction + ₹1.5 crore lab machinery). Initial packages start from ₹2 lakhs and can go up to ₹20 lakhs depending on complexity. On margins, Q1 EBITDA was impacted by a one-time aggressive pan-India marketing push for the AI tools (Sid & Erica), which was crucial to capture first-mover advantage. (Rakesh Kumar Sharma, Manika Khanna)
Technology USP (Sid & Erica)
- Question: Are we the only players with the AI technology, and what are the benefits for clients? (Priyansh Miri, NGP Family Office)
- Answer: Yes, we are the first in India to integrate Sid and Erica, certified by IVF 2.0. The AI tools assist embryologists in real-time sperm selection (Sid) and embryo assessment (Erica), improving the chances of success at the first attempt by ~8% in early results. This standardization also helps replicate precision across new centers. (Manika Khanna)
Key Takeaway
Gaudium IVF reported a subdued Q1 FY27 with 9.1% YoY revenue growth to ₹19.4 crores, a deliberate slowdown as management front-loaded expansion costs—including the operationalization of the South Extension hub, a one-time marketing push for its first-in-India AI embryology tools (Sid & Erica), and preparatory expenses for upcoming hubs—which compressed adjusted EBITDA margins from 29% to 12.5%. The company maintains a debt-light balance sheet with a D/E of 0.4x and reaffirmed its FY27 guidance of ~30% revenue growth and a return to steady-state margins, driven by the ramping of new hubs (Gurgaon & Nagpur imminent) and the anticipated benefits of its Signature Lab model. Strategic focus remains on replicating its high clinical success rates (62% first-attempt) through AI-integrated standardized protocols, with a board-approved ₹15 crore women's hospital in Lucknow as a related diversification. Key watch points include the execution of the 10-hub rollout timeline, the realization of growth in seasonally stronger quarters, and the cadence of ART Act implementation to drive industry consolidation.